Requests for individual funding can sometimes be used as a means of getting a treatment prescribed that is not routinely offered by the NHS or has not yet been appraised by NICE in England or Wales, or the Scottish Medicines Consortium (SMC) in Scotland.

Intrathecal baclofen may be used to treat spasticity in multiple sclerosis, it involves surgically implanting a pump under the skin of the abdomen. Learn more in this A-Z entry.

Immunoglobulins are antibodies that can be given into the bloodstream to treat some autoimmune conditions. This treatment is not commonly used for MS in the UK

Ixazomib is being tested in the Sizomus study as a potential treatment for relapsing and progressive multiple sclerosis (MS). Find out more in this A-Z page.

The JC virus is a common infection unrelated to MS. Some MS drugs can weaken your ability to keep JC virus under control, which can lead to a rare but serious brain infection known as PML.

Kalawalla is the brand name of an herbal supplement derived from a type of fern native to Central and South America.

Kesimpta (ofatumumab) is a disease modifying drug treatment for relapsing remitting MS. You take Kesimpta as an injection under the skin once a month.

Lamotrigine is an anti-epileptic drug that has been used experimentally in multiple sclerosis to reduce the pain associated with trigeminal neuralgia and spasticity. Lamotrigine is not currently recommended in the NICE Guideline for the treatment of pain in MS.

Laquinimod was developed as a treatment for multiple sclerosis. Following disappointing clinical trial results, the manufacturer discontinued development of it in MS.